Urethral Neoplasms: all 81 studies

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• DESTINY-PANTUMOUR04RecruitingNCT07124000
• Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaRecruitingNCT06983210Phase 2
• 64Cu-GRIP B in Patients With Advanced MalignanciesRecruitingNCT05888532Phase 1/2
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
• Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerCompletedNCT03617913Phase 2Results posted
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateActive, not recruitingNCT03582475Phase 1Results posted
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 2Results posted
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03219333Phase 2Results posted
• LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial CancerTerminatedNCT02612194Phase 2Results posted
• Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder CancerCompletedNCT02300610Phase 1Results posted
• Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by SurgeryCompletedNCT02178241Phase 2Results posted
• Afatinib in Advanced Refractory Urothelial CancerTerminatedNCT02122172Phase 2Results posted
• Cabozantinib for Advanced Urothelial CancerCompletedNCT01688999Phase 2Results posted
• Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder CancerTerminatedNCT01611662Phase 2Results posted
• A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerCompletedNCT01326871Phase 1/2Results posted
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00942331Phase 3Results posted
• Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial CancerCompletedNCT00749892Phase 2Results posted
• A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder CancerCompletedNCT00661609Phase 2Results posted
• Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney FunctionCompletedNCT00478361Phase 2Results posted
• Pazopanib in Treating Patients With Metastatic Urothelial CancerCompletedNCT00471536Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumCompletedNCT00407485Phase 2Results posted
• Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the UrotheliumCompletedNCT00397488Phase 2Results posted
• Sorafenib in Treating Patients With Regional or Metastatic Cancer of the UrotheliumTerminatedNCT00112905Phase 2Results posted
• S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the UrotheliumCompletedNCT00045630Phase 2Results posted
• S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary TractTerminatedNCT00022633Phase 2Results posted
• Agnostic Therapy in Rare Solid TumorsActive, not recruitingNCT06638931Phase 2
• A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of InterestCompletedNCT05899361Not applicable
• Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyActive, not recruitingNCT05092958Phase 3
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 2
• Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaActive, not recruitingNCT04848519Phase 2
• Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial CarcinomaActive, not recruitingNCT04004442Phase 1
• MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the TumourStatus unknownNCT03934827Phase 1
• Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial CarcinomaStatus unknownNCT03296306Phase 3
• Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial CarcinomaActive, not recruitingNCT03291028
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerTerminatedNCT03288545Phase 1/2
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT03237780Phase 2
• Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryActive, not recruitingNCT02812420Early Phase 1
• A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal FunctionCompletedNCT02665039Phase 2
• UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearchCompletedNCT02643043Not applicable
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial CancerCompletedNCT02437370Phase 1
• Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung CancersCompletedNCT01846520Not applicable
• Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial TractCompletedNCT01844947Phase 1
• Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial CancerWithdrawnNCT01639521Phase 2
• Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 1
• Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract CancerCompletedNCT01191892Phase 2
• Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract CancerStatus unknownNCT01118039Phase 2
• Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the UrotheliumCompletedNCT01090466Phase 1/2
• Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)CompletedNCT01089088Phase 2
• Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to TreatmentCompletedNCT01031875Phase 2
• Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy ParticipantsCompletedNCT00900276
• Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid TumorsCompletedNCT00479128Phase 1
• S0400, FR901228 in Treating Patients With Advanced Cancer of the UrotheliumTerminatedNCT00087295Phase 2
• Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the UrotheliumCompletedNCT00082719Phase 1
• Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal RemnantActive, not recruitingNCT00082706Phase 2
• Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the UrotheliumCompletedNCT00080795Phase 2
• TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the UrotheliumCompletedNCT00077688Phase 2
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With ChemotherapyCompletedNCT00066612Phase 2
• S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the UrotheliumCompletedNCT00055835Phase 2
• Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the UrotheliumCompletedNCT00053209Phase 2
• Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract CancerCompletedNCT00022191Phase 3
• Ixabepilone in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00021099Phase 2
• Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the UrotheliumCompletedNCT00014274Phase 2/3
• S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00014144Phase 2
• Arsenic Trioxide in Treating Patients With Urothelial CancerCompletedNCT00009867Phase 2
• SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00006351Phase 2
• Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary TractCompletedNCT00006111Phase 2
• Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary TractCompletedNCT00006026Phase 2
• Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney FunctionCompletedNCT00005644Phase 2
• Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the UrotheliumTerminatedNCT00004856Phase 2
• Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder CancerCompletedNCT00004223Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Combination Chemotherapy in Treating Patients With Bladder CancerCompletedNCT00003701Phase 3
• Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the UrotheliumCompletedNCT00003376Phase 3
• Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder CancerCompletedNCT00003175Phase 2
• Piritrexim in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00002914Phase 2
• Combination Chemotherapy in Patients With Advanced Urinary Tract CancerCompletedNCT00002684Phase 2

← Urethral Neoplasms overview